Validating a new CLCI tool for dermatology outpatients
Research type
Research Study
Full title
Psychometric analysis of the Questionnaire on Cumulative Live Course Impairment (DermCLCI-r) in patients with psoriasis, atopic dermatitis and hidradenitis suppurativa
IRAS ID
319747
Contact name
Richard Warren
Contact email
Sponsor organisation
Northern Care Alliance NHS Foundation Trust
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Skin diseases such as psoriasis, hidradenitis suppurativa and atopic dermatitis are life-long conditions with a relapsing remitting course. The visible, chronic and often highly symptomatic nature of these diseases can impact on many aspects of patients’ lives such as physical and mental wellbeing, quality of life, education, employment, finances and relationships. The overall impact on an individual over time is referred to as Cumulative Life-Course Impairment (CLCI), however there are currently no ways to accurately capture these longitudinal effects over. A new psychometric, patient-reported-outcome tool has been created aimed at quantifying CLCI and identifying patients at highest risk of progression to allow earlier appropriate interventions. The validation process of the new CLCI tool will involve simultaneous delivery of the questionnaire, alongside existing patient-reported-outcome psychometric tools, in 300 secondary care patients with psoriasis (n=100), hidradenitis suppurativa (n=100) and atopic dermatitis (n=100). These data will act as validation of data collected by collaborators in Germany. The CLCI tool will be analysed to assess validity using Item-Response-Theory.
REC name
London - Brent Research Ethics Committee
REC reference
23/LO/0329
Date of REC Opinion
12 May 2023
REC opinion
Further Information Favourable Opinion